Dong Woo Shin1,2, Min Jae Kim1, Jong-Chan Lee1, Jaihwan Kim1, Sang Myung Woo3, Woo Jin Lee3, Kwang Hyuck Lee4, Jin-Hyeok Hwang1. 1. Department of Internal Medicine, Division of Gastroenterology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam. 2. Department of Internal Medicine, Division of Gastroenterology, Keimyung University School of Medicine, Keimyung University Dongsan Medical Center, Daegu. 3. Center for Liver Cancer, National Cancer Center, Goyang. 4. Department of Internal Medicine, Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Abstract
OBJECTIVES: Gemcitabine plus cisplatin (GC) is recommended as first-line treatment for advanced cholangiocarcinoma. We investigated the impact of GC in patients with unresectable hilar cholangiocarcinoma (HC) based on the time taken for effective biliary drainage (EBD). MATERIALS AND METHODS: We retrospectively enrolled 113 patients with unresectable HC. Thirty-nine and 74 patients received GC chemotherapy and best supportive care (BSC), respectively. EBD was defined as a reduction in total bilirubin >50% or to a value <2 mg/dL after the drainage procedure. Early EBD (eEBD) and delayed EBD (dEBD) were separated by 2 weeks. Overall survival (OS) was estimated. RESULTS: The GC group showed a significantly longer median OS than the BSC group (12.8 vs. 6.1 mo; P<0.001). Moreover, the eEBD group experienced a significantly longer OS than the dEBD group (8.2 vs. 4.3 mo; P<0.001). GC led to improved OS in the eEBD (12.8 vs. 6.8 mo; P=0.003) and dEBD (12.2 vs. 3.4 mo; P=0.009) groups. In multivariate analysis, dEBD (adjusted hazard ratio [aHR], 1.785; 95% confidence interval [CI], 1.183-2.691; P=0.006), BSC (aHR, 2.409; 95% CI, 1.579-3.675; P<0.001), and an ECOG status ≥2 (aHR, 3.721; 95% CI, 2.093-6.615; P<0.001) were associated with poor prognosis. In GC group, the older (70 y and above) patients did not have a higher risk of death than younger patients. CONCLUSIONS: GC prolongs the survival of patients with unresectable HC, even those with dEBD or elderly.
OBJECTIVES:Gemcitabine plus cisplatin (GC) is recommended as first-line treatment for advanced cholangiocarcinoma. We investigated the impact of GC in patients with unresectable hilar cholangiocarcinoma (HC) based on the time taken for effective biliary drainage (EBD). MATERIALS AND METHODS: We retrospectively enrolled 113 patients with unresectable HC. Thirty-nine and 74 patients received GC chemotherapy and best supportive care (BSC), respectively. EBD was defined as a reduction in total bilirubin >50% or to a value <2 mg/dL after the drainage procedure. Early EBD (eEBD) and delayed EBD (dEBD) were separated by 2 weeks. Overall survival (OS) was estimated. RESULTS: The GC group showed a significantly longer median OS than the BSC group (12.8 vs. 6.1 mo; P<0.001). Moreover, the eEBD group experienced a significantly longer OS than the dEBD group (8.2 vs. 4.3 mo; P<0.001). GC led to improved OS in the eEBD (12.8 vs. 6.8 mo; P=0.003) and dEBD (12.2 vs. 3.4 mo; P=0.009) groups. In multivariate analysis, dEBD (adjusted hazard ratio [aHR], 1.785; 95% confidence interval [CI], 1.183-2.691; P=0.006), BSC (aHR, 2.409; 95% CI, 1.579-3.675; P<0.001), and an ECOG status ≥2 (aHR, 3.721; 95% CI, 2.093-6.615; P<0.001) were associated with poor prognosis. In GC group, the older (70 y and above) patients did not have a higher risk of death than younger patients. CONCLUSIONS:GC prolongs the survival of patients with unresectable HC, even those with dEBD or elderly.
Authors: Rocio I R Macias; Maria J Monte; Maria A Serrano; Jesús M González-Santiago; Isabel Martín-Arribas; André L Simão; Rui E Castro; Javier González-Gallego; José L Mauriz; Jose J G Marin Journal: Aging (Albany NY) Date: 2021-10-11 Impact factor: 5.682
Authors: David M de Jong; Jeska A Fritzsche; Amber S Audhoe; Suzanne S L Yi; Marco J Bruno; Rogier P Voermans; Lydi M J W van Driel Journal: Cancers (Basel) Date: 2022-04-21 Impact factor: 6.639